Pharmafit Provence
FONX 1 % Cream in Tube T/15g
Back to the catalogue

FONX 1 % Cream in Tube T/15g

VIDAL information
Your professional account

PharmaFit supplies pharmacies and healthcare professionals. Access your purchasing terms and availability through your professional account.

Access is reserved for authorised professionals, following account approval.

Contact PharmaFit

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
Update of 18/02/2025

FONX®
oxiconazole


Forms and presentations

Cream at 1 % :  Tube of 15 g.


Composition

  p 100 g
Oxiconazole 
1 g
(as oxiconazole nitrate: 1,147 g/100 g)
Excipients: stearyl alcohol, cetyl alcohol, pharmaceutical vaseline, polysorbate 60, propylene glycol, benzoic acid, purified water.

Excipients with known effect: this medicine contains 120 mg of stearyl alcohol, 45 mg of cetyl alcohol, 115 mg of propylene glycol and 2 mg of benzoic acid per gram of cream.


Indications

- Candidoses:
The candidoses encountered in human clinical practice are usually due to Candida albicans. However, the detection of a Candida on the skin cannot in itself constitute an indication.
Treatment:
  • intertrigo, particularly genito-crural, anal and perianal,
  • perlèche.
In some cases, it is recommended to simultaneously treat the digestive tract.
Adjunctive treatment of onychia and perionychia.
- Dermatophytoses:
  • dermatophytoses of glabrous skin (tinea corporis),
  • genital and crural intertrigo,
  • intertrigo of the toes (athlete's foot).
- Pityriasis versicolor.
The preferred indications for the cream are dry and desquamating lesions.

Dosage and administration

1 application per day after washing with a non-acidic soap and drying the skin. The duration of treatment depends on the infecting organisms and the sites of infection: generally 3 weeks for dermatophytoses, 2 weeks for the Pityriasis versicolor and candidiasis.


Contraindications

Hypersensitivity to imidazole derivatives or to any of the excipients mentioned in section Composition.

Warnings and precautions

Precautions for use

Avoid using acid-pH soaps, which promote the proliferation of Candida.

Avoid applications near the eyes.

This medicine contains 2 mg of benzoic acid per gram of cream. Benzoic acid may cause local irritation. Benzoic acid may increase the risk of jaundice (yellowing of the skin and eyes) in newborns (up to 4 weeks).

This medicine contains cetyl alcohol and stearyl alcohol and may cause local skin reactions (for example: contact dermatitis).

This medicine contains 115 mg of propylene glycol per gram of cream.


Interactions

The data available to date do not suggest the existence of clinically significant interactions.


Fertility, pregnancy and breastfeeding

Pregnancy:

Although no teratogenic effect has been observed in animal studies, it is recommended not to administer this product during the first trimester of pregnancy.



Driving and using machines

The effects on the ability to drive vehicles and use machines have not been studied.
No effect on the ability to drive vehicles or use machines is expected.

Adverse effects

Some signs of local irritation (pruritus, burning, erythema) have been reported; they resolve spontaneously upon discontinuation of treatment.

The occurrence of systemic effects is unlikely given the low rate of absorption through intact skin; however, use with caution over a large surface area or on damaged skin, particularly in infants (due to the surface-area-to-weight ratio and the occlusive effect of diapers).

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.


Overdose

There is no clinical data on the effects of overdose.


Pharmacodynamics

Pharmacotherapeutic class: antifungal of the imidazole class, ATC code: D01AC11.

  • Fungicide: Trichophyton mentagrophytes, Candida albicans.
  • Antibacterial: Staphylococcus aureus, Streptococcus faecalis.

Pharmacokinetics

Low transepidermal penetration (< 1 %).

Plasma concentration not quantifiable.

22 % of the applied dose is retained in the superficial layers of the skin.

Transcutaneous passage may be increased in cases of damaged skin.


Preclinical safety

Non-clinical data from conventional studies of pharmacology, safety, repeated-dose toxicology, genotoxicity, carcinogenesis and reproductive function did not reveal any particular risk for humans.


Storage conditions

Shelf life
3 years.

Store at room temperature.


HANDLING/DISPOSAL INSTRUCTIONS

No special requirements.


Prescription, supply and reimbursement

LIST I
Marketing authorisation (AMM) 3400933386856 (1991, SmPC rev 30.03.2021).
   
Price: 2,94 euros
Social Security reimbursement at 30%. Collect.

Marketing authorisation holder: Karo Pharma AB, Box 16184, 103 24 Stockholm, Sweden.


ALLOGA FRANCE
ZAC de Chapotin Sud
Rue du Professeur-Dargent. 69970 Chaponnay
Medical Information:
Tel: 01 81 79 38 34
www.alloga.fr

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.